Publication: An overview of current treatment strategies for β-thalassemia
Issued Date
2014-01-01
Resource Type
ISSN
21678707
Other identifier(s)
2-s2.0-84903306695
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Opinion on Orphan Drugs. Vol.2, No.7 (2014), 665-679
Suggested Citation
Maria Domenica Cappellini, Vip Viprakasit, Ali T. Taher An overview of current treatment strategies for β-thalassemia. Expert Opinion on Orphan Drugs. Vol.2, No.7 (2014), 665-679. doi:10.1517/21678707.2014.918503 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34772
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
An overview of current treatment strategies for β-thalassemia
Other Contributor(s)
Abstract
Introduction: At least 40,000 people per year worldwide are born with β-thalassemia. Patients with β-thalassemia major are reliant on regular red blood cell transfusions for survival from a young age. For those with β-thalassemia intermedia or hemoglobin (Hb) E/β-thalassemia, symptoms range from mild clinical presentation to a more severe phenotype and patients are not necessarily transfusion-dependent.Areas covered: Here, β-thalassemia treatment strategies including transfusion, splenectomy, fetal hemoglobin induction, hematopoietic stem-cell transplantation, in addition to potential future treatment options, are reviewed. Approaches for the monitoring and management of complications are also described.Expert opinion: The most important advances in the treatment of transfusion-dependent β-thalassemia major patients since the advent of iron chelation therapy are the introduction of oral iron chelators in addition to technologies for the direct measurement of iron in organs. For non-transfusion-dependent patients with β-thalassemia intermedia or HbE/β-thalassemia, recent studies have highlighted the significance of iron overload-related complications and the increase in incidence with advancing age, prompting the development of much-needed clinical treatment guidelines. Future research should focus on improving the treatment of β-thalassemia major patients to further extend survival and quality of life, and continued identification of β-thalassemia intermedia or HbE/β-thalassemia patients who may benefit from transfusion and iron chelation therapy. © 2014 Informa UK, Ltd.